Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 18/20 | 0.82 |
| ▸ | PTGDR | Q13258 | 15/20 | 0.82 |
| ▸ | PDE2A | O00408 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9518806 | 0.90 | TBXA2R (1.00) | TBXA2RPTGDRPDE2AMEN1ALDH1A1 | |
| SCHEMBL9518358 | 0.88 | TBXA2R (0.85) | TBXA2RPTGDRPDE2A | |
| SCHEMBL9277313 | 0.86 | TBXA2R (1.00) | TBXA2RPTGDRPDE2A | |
| SCHEMBL9518334 | 0.84 | TBXA2R (0.79) | TBXA2RPTGDRPDE2A | |
| SCHEMBL9518347 | 0.84 | TBXA2R (0.79) | TBXA2RPTGDRPDE2A | |
| SCHEMBL10413594 | 0.84 | TBXA2R (0.96) | TBXA2RPTGDRPDE2A | |
| SCHEMBL9518236 | 0.83 | TBXA2R (0.78) | TBXA2RPTGDRPDE2A | |
| SCHEMBL9518216 | 0.82 | TBXA2R (0.73) | TBXA2RPTGDRPDE2A | |
| SCHEMBL9521476 | 0.81 | TBXA2R (1.00) | TBXA2RPTGDRPDE2A | |
| SCHEMBL9518365 | 0.81 | TBXA2R (0.75) | TBXA2RPTGDRPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| EP-3175856-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS | The Trustees of the University of Pennsylvania (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2037967-B1 | PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS FOR TREATING ANDROGENETIC ALOPECIA | UNIV PENNSYLVANIA (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-12-01 | — | — | US | disclosed |
| US-9254293-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-20110021599-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-01-27 | — | — | US | disclosed |
| US-20070299122-A1 | Method of Treating Pathological Blushing | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | CHENG KANG (US) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021599-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | AR, BPHL, PTGS2 | TBXA2R 888/4885PTGDR 10/4885PDE2A 558/4885 |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | AR, BPHL, PTGS2 | TBXA2R 888/4885PTGDR 10/4885PDE2A 558/4885 |
| US-20070299122-A1 | Method of Treating Pathological Blushing | BDKRB2, BDKRB1, PTGIR | TBXA2R 9/4885PTGDR 11/4885PDE2A 330/4885 |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | TBXA2R 53/4885PTGDR 518/4885PDE2A 1181/4885 |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | AR, BPHL, PTGS2 | TBXA2R 888/4885PTGDR 10/4885PDE2A 558/4885 |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | TBXA2R 37/4885PTGDR 201/4885PDE2A 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.